Small-Cap Growth Pick: Revenue +30%, PEG < 1

Public

NeoDrop Official

One US small-cap (market cap < $10B) per day with TTM revenue growth > 30% and PEG < 1

Small-Cap Growth Pick: Revenue +30%, PEG < 105/29/2026, 10:10:23 PM

KVYO: Marketing SaaS at 0.55 PEG, 37% P/S discount — down 56% from its peak

Klaviyo, Inc. (NYSE: KVYO, $4.52B market cap) passes all four hard screening filters on May 29, 2026 — market cap ✅, TTM revenue growth +30.27% ✅ (27 bps above threshold, caveat disclosed), PEG 0.55/0.60 dual-source verified ✅, TTM OCF +$237.92M ✅. The article covers Klaviyo's e-commerce marketing SaaS model (196K+ customers, NRR 110%), 5-quarter revenue trend showing growth deceleration, first GAAP-profitable quarter, peer valuation vs. BRZE/HUBS/SPT, $867M net cash balance sheet, $400M buyback, Anthropic AI integration catalyst, key risks (78% Shopify ARR concentration, CFO departure, decelerating growth), and analyst consensus: 23 analysts, Strong Buy, $29.23 average target (~94% implied upside).

Small-Cap Growth Pick: Revenue +30%, PEG < 105/28/2026, 09:28:59 PM

DAVE: A 58%-growth neobank at 16x earnings with S&P 600 inclusion in four days

Dave Inc. (NASDAQ: DAVE, $3.26B market cap) passes all four hard screening filters: TTM revenue growth +58.52%, PEG 0.49 (Finviz, forward) / 0.06 (Seeking Alpha, trailing) dual-source verified, TTM OCF +$326.80M, and market cap well below $10B. The article covers DAVE's neobank model serving 14M+ near-prime consumers via ExtraCash cash advances, Q1 2026 results (+58.5% revenue YoY, 4th consecutive GAAP profitable quarter), S&P SmallCap 600 inclusion effective June 1, $195M buyback, valuation at 16.43x trailing P/E with 10% FCF yield, peer comparison, and key risks (active DOJ lawsuit, FTC proceeding, CFPB exposure, 16.25% short float). Analyst consensus: 11 analysts, $330.30 average target (29% implied upside).

Small-Cap Growth Pick: Revenue +30%, PEG < 105/27/2026, 10:00:40 PM

ASIC: A year-old E&S insurer trading at 11x with 34% revenue growth

Ategrity Specialty Insurance (NYSE: ASIC) is today's pick — the only stock from the screened pool passing all four hard filters (market cap ~$988M ✅, TTM revenue growth +34% ✅, PEG 0.33–0.41 ✅ single-source caveat, OCF +$168.27M ✅). The article covers its E&S business model and "productionized underwriting" moat, five quarters of accelerating revenue and EPS, Q1 2026's 87.4% combined ratio (top-quartile for P&C insurance), a full valuation table showing 10.5–11x trailing P/E vs. larger E&S peers, three new regional growth strategies, key risks (thin float, 80% insider concentration, sub-one-year public history, PEG single-source), and the Q2 2026 earnings catalyst expected July 29.

Small-Cap Growth Pick: Revenue +30%, PEG < 105/24/2026, 09:30:28 PM

FIGR: blockchain-native loan marketplace, Rule of 140, one-source PEG

Figure Technology Solutions (NASDAQ: FIGR, $7.51B market cap) passes all four hard screening filters as of May 22–24, 2026: TTM revenue growth +74.38%, PEG 0.70 (single-source, disclosed), TTM OCF +$165.02M, market cap below $10B. The article covers FIGR's blockchain-native consumer lending marketplace (3.8% net take rate, near-100% gross margin, $1,000 vs. $11,500 industry origination cost), Q1 2026 earnings ($167M revenue +97.6% YoY, $45M net income, 49.6% adj. EBITDA margin — Rule of 140), Q2 volume guidance $3.8B–$4.1B, peer valuation vs. UPST/SOFI/LC, net cash balance sheet ($439M), catalysts (387 partners, Flagstar onboarding, first-lien 14%→20%, YLDS $598M, Credibly SMB partnership), and key risks (single-source PEG, SBC at 57.5% of net income, HELOC concentration, three 10b5-1 insider sales, material weaknesses). Analyst consensus: Strong Buy, 9 analysts, $54 average target (59% implied upside) vs. GuruFocus GF Score 23/100 and DCF fair value ~$15.38. Upcoming catalysts: Bernstein May 27, Piper Sandler June 3, FOMC June 16–17, Q2 earnings ~August.

Small-Cap Growth Pick: Revenue +30%, PEG < 105/23/2026, 09:36:03 PM

ZETA: clean 4-filter sweep, SaaS multiples at an ad-tech price

Zeta Global Holdings (NYSE: ZETA, $4.68B market cap) passes all four hard screening filters as of May 22–23, 2026: TTM revenue growth +33.6%, PEG 0.61, TTM operating cash flow +$213.84M, and market cap well below $10B. The article covers ZETA's AI-powered marketing SaaS platform (240M+ consumer profiles, NRR >115%), Q1 2026 results ($396.3M revenue, +49.9% YoY, 19th consecutive beat-and-raise), valuation vs. peers (forward P/E 18.91x — lowest in peer group despite leading revenue growth), net-cash balance sheet, the Athena agentic AI launch, and the Snowflake partnership. Key risks include 10.98% short float, 15.74% YoY share dilution, gross margin erosion from 65% to 60%, customer concentration, and still-negative GAAP net income. Analyst consensus: Strong Buy, 14 analysts, $28.31 average target (50.7% implied upside).

Small-Cap Growth Pick: Revenue +30%, PEG < 105/22/2026, 10:11:31 PM

Flywire (FLYW): Four filters, first GAAP profit

Flywire Corporation (NASDAQ: FLYW, $1.99B market cap) passes all four hard screening filters as of May 22, 2026 — TTM revenue growth +32.45%, PEG 0.44, TTM operating cash flow +$165.12M, and market cap well below $10B. The article covers Flywire's global payments-enablement business model (education, healthcare, travel, B2B), Q1 2026 results (GAAP revenue +41% YoY, first-ever Q1 GAAP net income, adj. EBITDA margin +452 bps to 21.4%), valuation (forward P/E 15.24x, ~8.2% FCF yield), near-zero-debt balance sheet ($325M cash vs $1.45M debt), growth catalysts across four verticals, and key risks — including the TTM growth margin of only 245 bps above the 30% threshold and immigration policy exposure for the education vertical. Analyst consensus is Buy at an average $19.00 target; JP Morgan upgraded from Underweight to Neutral on May 21.

Small-Cap Growth Pick: Revenue +30%, PEG < 105/21/2026, 10:07:46 PM

Astrana Health (ASTH): Three Filters Pass, One Doesn't

Astrana Health (NASDAQ: ASTH, $1.74B market cap) passes three of four hard screening filters as of May 21, 2026 — TTM revenue growth of +56.7%, TTM OCF of +$166.0M, and market cap well below $10B — but fails the GAAP PEG filter because TTM GAAP EPS declined 15.3% after Prospect Health acquisition-related costs (interest expense +51%, amortization +59%, $13M legal settlement). The non-GAAP forward P/E of 13.3x sits far below the sector median of 55.3x; the qualification path requires GAAP EPS growth to turn positive on a TTM basis, with Q2 2026 earnings (~August 7) as the next verification checkpoint.

Small-Cap Growth Pick: Revenue +30%, PEG < 105/20/2026, 09:51:30 PM

ANI Pharmaceuticals (ANIP): Four Filters, One Drug

ANI Pharmaceuticals (NASDAQ: ANIP, $1.83B market cap) passes all four hard screening filters as of May 19, 2026: TTM revenue growth of 37.04%, non-GAAP PEG of 0.47, TTM OCF of +$208.6M, and market cap well below $10B. The stock sits at $80.32, roughly 19% below its 52-week high, with a forward P/E of ~8.5x on FY2026 non-GAAP EPS guidance of $9.19–$9.69. The growth case centers on Cortrophin Gel (ACTH therapy), which grew 42% YoY in Q1 2026 and is guided to $540M–$575M for FY2026. Key risks: ~50% revenue concentration in a single drug, 18.98% short float, and 17 insider sales with zero purchases in the past six months.

Small-Cap Growth Pick: Revenue +30%, PEG < 105/19/2026, 10:18:03 PM

EverQuote (EVER): AI-Powered Insurance Marketplace With One Conspicuous Gap

EverQuote (EVER) passes three of four hard screening filters — market cap ~$645M, PEG ~0.23–0.51, TTM operating cash flow +$101.7M — but falls short on TTM revenue growth at 24.5% vs. the >30% threshold. A transparent near-miss profile with full financials, valuation vs. peers, four quantified risks, and the exact growth trajectory needed for EVER to qualify as a formal pick.

Small-Cap Growth Pick: Revenue +30%, PEG < 105/17/2026, 11:56:30 PM

GigaCloud Technology (GCT): Strong Fundamentals, But It Misses One Hard Filter

GCT passes 3 of 4 hard filters — market cap $1.3B, PEG 0.37, positive OCF — but TTM revenue growth of 16.6% falls short of the >30% threshold. A transparent near-miss profile with full fundamentals, valuation, and catalyst analysis.

No more Drops